All Stories

  1. Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects
  2. Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies
  3. YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge
  4. Discovery of Acyl-Indole Derivatives as Pan-Serotype Dengue Virus NS4B Inhibitors
  5. Author Correction: Reverse engineering synthetic antiviral amyloids
  6. Towards antivirals against hepatitis E: In the steps of hepatitis C
  7. Antiviral strategies for epidemic and pandemic preparedness
  8. Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters
  9. Immunovirological and environmental screening reveals actionable risk factors for fatal COVID-19 during post-vaccination nursing home outbreaks
  10. Urtica dioica Agglutinin Prevents Rabies Virus Infection in a Muscle Explant Model
  11. Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment
  12. Validation of a Reporter Cell Line for Flavivirus Inhibition Assays
  13. Anti-SARS-CoV-2 Activity and Cytotoxicity of Amaryllidaceae Alkaloids from Hymenocallis littoralis
  14. Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates
  15. Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2
  16. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
  17. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
  18. Insertion of an Amphipathic Linker in a Tetrapodal Tryptophan Derivative Leads to a Novel and Highly Potent Entry Inhibitor of Enterovirus A71 Clinical Isolates
  19. A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships
  20. Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery
  21. Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge
  22. Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells
  23. Rational design of novel nucleoside analogues reveals potent antiviral agents for EV71
  24. Synthesis, characterization, molecular docking, and anticancer activities of new 1,3,4-oxadiazole-5-fluorocytosine hybrid derivatives
  25. Structural Investigations on Novel Non-Nucleoside Inhibitors of Human Norovirus Polymerase
  26. Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors
  27. The Role of Histo-Blood Group Antigens and Microbiota in Human Norovirus Replication in Zebrafish Larvae
  28. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
  29. Anatomical barriers against SARS-CoV-2 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 patients
  30. Human Norovirus Efficiently Replicates in Differentiated 3D-Human Intestinal Enteroids
  31. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
  32. Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters
  33. Synthesis and evaluation of 3-alkynyl-5-aryl-7-aza-indoles as broad-spectrum antiviral agents
  34. Bis(Benzofuran–1,3-N,N-heterocycle)s as Symmetric and Synthetic Drug Leads against Yellow Fever Virus
  35. SARS-CoV-2 infection causes prolonged cardiomyocyte swelling and inhibition of HIF1α translocation in an animal model COVID-19
  36. Synthesis of new 3-acetyl-1,3,4-oxadiazolines combined with pyrimidines as antileishmanial and antiviral agents
  37. Modulation of thromboinflammation in hospitalized COVID‐19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn‐Antico study
  38. Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease
  39. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity
  40. Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19
  41. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models
  42. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection
  43. The pulmonary vasculature in lethal COVID-19 and idiopathic pulmonary fibrosis at single-cell resolution
  44. Evaluation of the anti-SARS-CoV-2 properties of essential oils and aromatic extracts
  45. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies
  46. The dissemination of Rift Valley fever virus to the eye and sensory neurons of zebrafish larvae is stat1 dependent
  47. Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
  48. Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
  49. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
  50. Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort
  51. Computer-Aided Design and Synthesis of (Functionalized quinazoline)–(α-substituted coumarin)–arylsulfonate Conjugates against Chikungunya Virus
  52. Organotropic dendrons with high potency as HIV-1, HIV-2 and EV-A71 cell entry inhibitors
  53. A High-Throughput Yellow Fever Neutralization Assay
  54. Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
  55. HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect
  56. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
  57. Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity
  58. SARS-CoV-2 Virion Infectivity and Cytokine Production in Primary Human Airway Epithelial Cells
  59. Restriction of viral replication, rather than T cell immunopathology, drives lethality in MNV CR6-infected STAT1-deficient mice
  60. Cytidine nucleoside analog is an effective antiviral drug against Trichomonasvirus
  61. Development and optimization of a high‐throughput screening assay for in vitro anti‐SARS‐CoV‐2 activity: Evaluation of 5676 Phase 1 Passed Structures
  62. Restriction of Viral Replication, Rather than T Cell Immunopathology, Drives Lethality in Murine Norovirus CR6-Infected STAT1-Deficient Mice
  63. Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model
  64. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
  65. The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model
  66. Synthesis, X-ray crystallographic analysis, DFT studies and biological evaluation of triazolopyrimidines and 2-anilinopyrimidines
  67. Synthesis and antiviral activities of quinazolinamine–coumarin conjugates toward chikungunya and hepatitis C viruses
  68. Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model
  69. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
  70. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses
  71. Synthesis, Structure–Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication
  72. Development and optimisation of a high-throughput screening assay for in vitro anti–SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures
  73. SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids
  74. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
  75. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
  76. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
  77. Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings
  78. Advances and gaps in SARS-CoV-2 infection models
  79. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
  80. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
  81. Antiviral Strategies Against (Non‐polio) Picornaviruses
  82. Antiviral Targets and Strategies to Treat and Prevent Human Norovirus Infections
  83. An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
  84. Evaluation of the anti-SARS-CoV-2 properties of essential oils and aromatic extracts.
  85. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
  86. Comparative analysis of the molecular mechanism of resistance to vapendavir across a panel of picornavirus species
  87. Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host
  88. The legacy of ZikaPLAN: a transnational research consortium addressing Zika
  89. Publisher Correction: A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction
  90. A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction
  91. A highly potent antibody effective against SARS-CoV-2 variants of concern
  92. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
  93. 1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors
  94. Discovery of a Novel Class of Norovirus Inhibitors with High Barrier of Resistance
  95. Assessing In Vitro Resistance Development in Enterovirus A71 in the Context of Combination Antiviral Treatment
  96. A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo
  97. Broad betacoronavirus neutralization by a stem helix–specific human antibody
  98. Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?
  99. Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues
  100. Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase
  101. Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections
  102. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
  103. A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice
  104. Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections
  105. Broad sarbecovirus neutralization by a human monoclonal antibody
  106. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
  107. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
  108. Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors
  109. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity
  110. Corrigendum to “itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens”
  111. Structural Insights into the Mechanisms of Action of Functionally Distinct Classes of Chikungunya Virus Nonstructural Protein 1 Inhibitors
  112. Discovery of novel furo[2,3‐ d ]pyrimidin‐2‐one–1,3,4‐oxadiazole hybrid derivatives as dual antiviral and anticancer agents that induce apoptosis
  113. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
  114. Multivalent Tryptophan‐ and Tyrosine‐Containing [60]Fullerene Hexa‐Adducts as Dual HIV and Enterovirus A71 Entry Inhibitors
  115. COVID-19 and the intensive care unit: vaccines to the rescue
  116. In vitro activity of itraconazole against SARS‐CoV‐2
  117. Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects
  118. Chemical Evolution of Antivirals Against Enterovirus D68 through Protein‐Templated Knoevenagel Reactions
  119. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
  120. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2
  121. Alpha variant versus D614G strain in the Syrian hamster model
  122. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
  123. Infection of zebrafish larvae with human norovirus and evaluation of the in vivo efficacy of small-molecule inhibitors
  124. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial
  125. Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors
  126. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
  127. High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients
  128. Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
  129. Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2
  130. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19
  131. Recent African strains of Zika virus display higher transmissibility and fetal pathogenicity than Asian strains
  132. Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages
  133. Identification of host factors binding to dengue and Zika virus subgenomic RNA by efficient yeast three-hybrid screens of the human ORFeome
  134. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice
  135. Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Early mechanistic studies
  136. Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Identification of active compounds
  137. Screening and in vitro antiviral assessment of small molecules against fluorescent protein-expressing Bunyamwera virus in a cell-based assay using high-content imaging
  138. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
  139. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
  140. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters
  141. Rational design of highly potent broad-spectrum enterovirus inhibitors targeting the nonstructural protein 2C
  142. A dengue type 2 reporter virus assay amenable to high-throughput screening
  143. Diketo acids inhibit the cap-snatching endonuclease of several Bunyavirales
  144. SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
  145. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
  146. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
  147. Identification of TMEM106B as proviral host factor for SARS-CoV-2
  148. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients
  149. Enterovirus Inhibition by Hinged Aromatic Compounds with Polynuclei
  150. Enhanced efficacy of endonuclease inhibitor baloxavir acid against orthobunyaviruses when used in combination with ribavirin
  151. A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate
  152. Establishing a Unified COVID-19 “Immunome”: Integrating Coronavirus Pathogenesis and Host Immunopathology
  153. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
  154. Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine
  155. Reverse engineering synthetic antiviral amyloids
  156. Antiviral and Cytotoxic Activity of Different Plant Parts of Banana (Musa spp.)
  157. Medical treatment options for COVID-19
  158. Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery
  159. STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters
  160. Antibacterial, Antifungal, Antiviral, and Anthelmintic Activities of Medicinal Plants of Nepal Selected Based on Ethnobotanical Evidence
  161. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies
  162. The Development of RNA-KISS, a Mammalian Three-Hybrid Method to Detect RNA–Protein Interactions in Living Mammalian Cells
  163. Antiviral drug discovery against arthritogenic alphaviruses: Tools and molecular targets
  164. Rational modifications, synthesis and biological evaluation of new potential antivirals for RSV designed to target the M2-1 protein
  165. Mycophenolic Acid Has Intrinsic Antiviral Properties and Potentiates the Antiviral Effect of Ribavirin on Parainfluenza Virus
  166. Quinolinecarboxamides Inhibit the Replication of the Bovine Viral Diarrhea Virus by Targeting a Hot Spot for the Inhibition of Pestivirus Replication in the RNA-Dependent RNA Polymerase
  167. Identification of 2-(4-(Phenylsulfonyl)piperazine-1-yl)pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus
  168. Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides
  169. Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication Structure-based design, synthesis, and activity assessment
  170. GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5: Entomological aspects
  171. Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site
  172. Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-a]pyrimidines as potential anti-chikungunya agents
  173. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice
  174. Increased IL‐10‐producing regulatory T cells are characteristic of severe cases of COVID‐19
  175. Monocyte-Driven Atypical Cytokine Storm and Aberrant Neutrophil Activation as Key Mediators of COVID19 Disease Severity
  176. Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study
  178. Design, synthesis and discovery of novel N,N’‐carbazoyl‐aryl‐urea inhibitors of Zika NS5 methyltransferase and virus replication
  179. Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach
  180. 2019 meeting of the global virus network
  181. GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2: Epidemiological distribution of o'nyong-nyong virus
  182. GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 3: Epidemiological distribution of Mayaro virus
  183. A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase
  184. Isolation of phenanthrenes and identification of phorbol ester derivatives as potential anti-CHIKV agents using FBMN and NAP from Sagotia racemosa
  185. A robust human norovirus replication model in zebrafish larvae
  186. Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum
  187. A chimeric Japanese encephalitis vaccine protects against lethal yellow fever virus infection without inducing neutralizing antibodies
  188. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines
  189. New HSV-1 Anti-Viral 1′-Homocarbocyclic Nucleoside Analogs with an Optically Active Substituted Bicyclo[2.2.1]Heptane Fragment as a Glycoside Moiety
  190. A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses
  191. Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid
  192. A Viral Polymerase Inhibitor Reduces Zika Virus Replication in the Reproductive Organs of Male Mice
  193. F-102 Antivirals, a lot has been achieved, yet a long way to go
  194. Pan-viral protection against arboviruses by targeting inoculation site-based skin macrophages
  195. GloPID-R report on Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics
  196. Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy
  197. Structural and functional similarities in bunyaviruses: Perspectives for pan-bunya antivirals
  198. Antiviral effects of selected nucleoside analogues against human parechoviruses A1 and A3
  199. Antiviral Compounds from Codiaeum peltatum Targeted by a Multi-informative Molecular Networks Approach
  200. A robust human norovirus replication model in zebrafish larvae: Supplementary data file
  201. Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication
  202. Progress in human picornavirus research: New findings from the AIROPico consortium
  203. Pyrimethamine inhibits rabies virus replication in vitro
  204. Intra-host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence
  205. ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas
  206. Limited evolution of the yellow fever virus 17d in a mouse infection model
  207. Human stem cell-derived hepatocyte-like cells support Zika virus replication and provide a relevant model to assess the efficacy of potential antivirals
  208. A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice
  209. Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice
  210. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer
  211. Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon-λ
  212. Assessing medicinal plants traditionally used in the Chirang Reserve Forest, Northeast India for antimicrobial activity
  213. A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission
  214. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases
  215. Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors
  216. Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication
  217. HCV-induced EGFR-ERK signaling promotes a pro-inflammatory and pro-angiogenic signature contributing to liver cancer pathogenesis
  218. A Single Nucleoside Viral Polymerase Inhibitor Against Norovirus, Rotavirus, and Sapovirus-Induced Diarrhea
  219. Antiplasmodial, Anti-chikungunya virus and Antioxidant Activities of 64 endemic Plants from the Mascarene Islands
  220. Identification of fukinolic acid from Cimicifuga heracleifolia and its derivatives as novel antiviral compounds against enterovirus A71 infection
  221. Identification of Broad-Spectrum Dengue/Zika Virus Replication Inhibitors by Functionalization of Quinoline and 2,6-Diaminopurine Scaffolds
  222. Antiviral effect of the nucleoside analogue cidofovir in the context of sexual transmission of a gammaherpesvirus in mice
  223. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
  224. Synthesis of Enantiomerically Pure 1′,2′-cis-dideoxy, -dideoxydi­dehydro, -ribo and -deoxy Carbocyclic Nucleoside Analogues
  225. Rational modifications on a benzylidene-acrylohydrazide antiviral scaffold, synthesis and evaluation of bioactivity against Chikungunya virus
  226. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe
  227. Hepatitis E virus replication and interferonresponse in human placental-derived cells
  228. Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium
  229. A reassessment of mycophenolic acid as a lead compound for the development of inhibitors of chikungunya virus replication
  230. Pan-NS3 protease inhibitors of hepatitis C virus based on an R 3 -elongated pyrazinone scaffold
  231. Structurally Diverse Diterpenoids from Sandwithia guyanensis
  232. Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones
  233. Design, synthesis and evaluation against Chikungunya virus of novel small-molecule antiviral agents
  234. Differential Antiviral Activities of RSV Inhibitors in Human Airway Epithelium
  235. Hepatitis E virus replication and interferon responses in human placental cells
  236. Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection
  237. Interferon lambda (IFN-λ) efficiently blocks norovirus transmission in a mouse model
  238. New Models to Study Hepatitis E Virus Replication and Particular Characteristics of Infection: The Needle Hides in the Hay Stack
  239. Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model
  240. Assessing the Efficacy of Small Molecule Inhibitors in a Mouse Model of Persistent Norovirus Infection
  241. The path towards effective antivirals against rabies
  242. Mannitol treatment is not effective in therapy of rabies virus infection in mice
  243. Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study
  244. New class of early-stage enterovirus inhibitors with a novel mechanism of action
  245. Antimicrobial, Anthelmintic, and Antiviral Activity of Plants Traditionally Used for Treating Infectious Disease in the Similipal Biosphere Reserve, Odisha, India
  246. Novel therapeutic approaches to simultaneously target rhinovirus infection and asthma/COPD pathogenesis
  247. Upregulation of sodium taurocholate cotransporter polypeptide during hepatogenic differentiation of umbilical cord matrix mesenchymal stem cells facilitates hepatitis B entry
  248. Bioactive Natural Products Prioritization Using Massive Multi-informational Molecular Networks
  249. Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals
  250. In silico development of a novel putative inhibitor of the 3C protease of Coxsackievirus B3 with a benzene sulfonamide skeleton
  251. Antiviral activity of [1,2,3]triazolo[4,5- d ]pyrimidin-7(6 H )-ones against chikungunya virus targeting the viral capping nsP1
  252. Fluorination of Naturally Occurring N6-Benzyladenosine Remarkably Increased Its Antiviral Activity and Selectivity
  253. Isolation of Premyrsinane, Myrsinane, and Tigliane Diterpenoids from Euphorbia pithyusa Using a Chikungunya Virus Cell-Based Assay and Analogue Annotation by Molecular Networking
  254. A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication
  255. A novel kindred with inherited STAT2 deficiency and severe viral illness
  256. Chikungunya virus infections: time to act, time to treat
  257. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase
  258. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication
  259. Tiyoüreler, açiltiyoüreler ve 4-tiyazolidinonların sentezi, karakterizasyonu ve antikanser ve antiviral etkilerinin değerlendirilmesi
  260. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307
  261. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery
  262. Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains
  263. Protein kinases C as potential host targets for the inhibition of chikungunya virus replication
  264. Structure-activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid
  265. Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases
  266. Shape-based virtual screening, synthesis and evaluation of novel pyrrolone derivatives as antiviral agents against HCV
  267. ZikaPLAN: Zika Preparedness Latin American Network
  268. Aminopurine and aminoquinazoline scaffolds for development of potential dengue virus inhibitors
  269. Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication
  270. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase
  271. Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones
  272. In vitro Assay to Assess Efficacy of Potential Antiviral Compounds against Enterovirus D68
  273. Antiviral Agents Towards Chikungunya Virus: Structures, Syntheses, and Isolation from Natural Sources
  274. Effect of hepatitis E virus infection on the human hepatic innate immune response in human liver chimeric mice
  275. Biosafety standards for working with Crimean-Congo hemorrhagic fever virus
  276. Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism
  277. Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication
  278. Synthetic strategy and antiviral evaluation of diamide containing heterocycles targeting dengue and yellow fever virus
  279. Norovirus genetic diversity and evolution: implications for antiviral therapy
  280. Towards antiviral therapies for treating dengue virus infections
  281. Zika Virus Replicons for Drug Discovery
  282. Zika and Other Emerging Viruses: Aiming at the Right Target
  283. Hydantoin: The mechanism of its in vitro anti-enterovirus activity revisited
  284. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity
  285. The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection
  286. 9-Norbornyl-6-chloropurine (NCP) induces cell death through GSH depletion-associated ER stress and mitochondrial dysfunction
  287. Inhibition of human norovirus by a viral polymerase inhibitor in the B cell culture system and in the mouse model
  288. Post-exposure antiviral treatment of norovirus infections effectively protects against diarrhea and reduces virus shedding in the stool in a mortality mouse model
  289. Viral Macro Domains Reverse Protein ADP-Ribosylation
  290. A rat model for hepatitis E virus
  291. Update on hepatitis E virology: Implications for clinical practice
  292. Cover Image
  293. Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease
  294. Reply
  295. VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection
  296. Optimization of a Class of Tryptophan Dendrimers That Inhibit HIV Replication Leads to a Selective, Specific, and Low-Nanomolar Inhibitor of Clinical Isolates of Enterovirus A71
  297. Antiviral Activity of Favipiravir (T-705) against a Broad Range of ParamyxovirusesIn Vitroand against Human Metapneumovirus in Hamsters
  298. The Viral Polymerase Inhibitor 7-Deaza-2’-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model
  299. 3-(imidazo[1,2- a :5,4- b ′]dipyridin-2-yl)aniline inhibits pestivirus replication by targeting a hot spot drug binding pocket in the RNA-dependent RNA polymerase
  300. Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
  301. Modification of the length and structure of the linker of N6-benzyladenosine modulates its selective antiviral activity against enterovirus 71
  302. The viral polymerase inhibitor 7-deaza-2'-C-methyladenosine is a potent inhibitor of in 1 vitro Zika virus replication and delays disease progression in a robust mouse infection model
  303. Stem cell-derived hepatocytes: A novel model for hepatitis E virus replication
  304. Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway
  305. Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death
  306. Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells
  307. Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus
  308. The Medicinal Chemistry of Dengue Virus
  309. Exploring the importance of zinc binding and steric/hydrophobic factors in novel HCV replication inhibitors
  310. Antiviral Strategies Against Chikungunya Virus
  311. Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries
  312. Identification and Analysis of Antiviral Compounds Against Poliovirus
  313. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
  314. PKCA/AP-1 Drives Transcription of Interferon-Stimulated Genes and Mediates Cell-Autonomous Defense against Hepatitis E Virus
  315. Treatment with a Nucleoside Polymerase Inhibitor Reduces Shedding of Murine Norovirus in Stool to Undetectable Levels without Emergence of Drug-Resistant Variants
  316. Novel symmetrical phenylenediamines as potential anti-hepatitis C virus agents
  317. The future of antivirals
  318. ID: 146
  319. Structure Elucidation of Coxsackievirus A16 in Complex with GPP3 Informs a Systematic Review of Highly Potent Capsid Binders to Enteroviruses
  320. Toward antiviral therapy/prophylaxis for rhinovirus-induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies
  321. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68
  322. Structure of Coxsackievirus A16 in complex with GPP3
  323. Towards antivirals against chikungunya virus
  324. LC-MS2-Based dereplication of Euphorbia extracts with anti-Chikungunya virus activity
  325. NMR-based conformational analysis of 2′,6-disubstituted uridines and antiviral evaluation of new phosphoramidate prodrugs
  326. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity
  327. In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance
  328. Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells
  329. The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis
  330. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses
  331. Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases
  332. Bicyclic and Tricyclic “Expanded” Nucleobase Analogues of Sofosbuvir: New Scaffolds for Hepatitis C Therapies
  333. The Enterovirus 3C Protease Inhibitor SG85 Efficiently Blocks Rhinovirus Replication and Is Not Cross-Resistant with Rupintrivir
  334. Benzouracil–coumarin–arene conjugates as inhibiting agents for chikungunya virus
  335. P200: Extrahepatic replication of hepatitis E virus in neuronal and placental cell lines
  336. HEV4 O-22: Human liver chimeric mice as a novel model for the study of hepatitis E virus infections
  337. P209: Near full-length hepatitis E virus genome sequencing analysis in a chronically infected patient following ribavirin treatment failure
  338. Tonantzitlolones from Stillingia lineata ssp. lineata as potential inhibitors of chikungunya virus
  339. Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication
  340. Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata
  341. Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP
  342. Molecular Chaperone Hsp90 Is a Therapeutic Target for Noroviruses
  343. Flaviviral NS4b, chameleon and jack‐in‐the‐box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention
  344. Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors
  345. Crystal Structure of Coxsackie Virus B3 3D polymerase in complex with GPC-N114 inhibitor
  346. Crystal Structure of Coxsackievirus B3 3D polymerase in complex with GPC-N143
  347. Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds
  348. I304V 3D polymerase mutant of EMCV
  349. M300V 3D polymerase mutant of EMCV
  350. P0488 : Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection
  351. P0692 : PKC/AP-1 signaling drives transcription of interferon-stimulated genes and exerts potent antiviral activity against hepatitis C and E viruses
  352. The RNA Template Channel of the RNA-Dependent RNA Polymerase as a Target for Development of Antiviral Therapy of Multiple Genera within a Virus Family
  353. Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors
  354. Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein
  355. Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral Infection
  356. Antiviral activity of cytokinin-like adenosine derivatives
  357. Reaching beyond HIV/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus
  358. New 1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides inhibit hepatitis C virus replication via suppression of cyclooxygenase-2
  359. Norbornane-based nucleoside and nucleotide analogues locked in North conformation
  360. A thiazepino[4,5-a]benzimidazole derivative hampers the RNA replication of Eurasian serotypes of foot-and-mouth disease virus
  361. Complete Genome Sequence of a Rat Hepatitis E Virus Strain Isolated in the United States
  362. A Mutation in the Hepatitis E Virus RNA Polymerase Promotes Its Replication and Associates With Ribavirin Treatment Failure in Organ Transplant Recipients
  363. Structure–activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication
  364. Synthesis and evaluation of imidazole-4,5- and pyrazine-2,3-dicarboxamides targeting dengue and yellow fever virus
  365. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1
  366. Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mTOR pathway
  367. Prophylactic treatment with the nucleoside analogue 2'-C-methylcytidine completely prevents transmission of norovirus
  368. The Capsid Binder Vapendavir and the Novel Protease Inhibitor SG85 Inhibit Enterovirus 71 Replication
  369. Norovirus: Targets and tools in antiviral drug discovery
  370. Tigliane diterpenes from Croton mauritianus as inhibitors of chikungunya virus replication
  371. A Refined Guinea Pig Model of Foot-and-Mouth Disease Virus Infection for Assessing the Efficacy of Antiviral Compounds
  372. A benzonitrile analogue inhibits rhinovirus replication
  373. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral
  374. A novel benzonitrile analogue inhibits rhinovirus replication
  375. Jatrophane Diterpenes as Inhibitors of Chikungunya Virus Replication: Structure–Activity Relationship and Discovery of a Potent Lead
  376. The Enterovirus Protease Inhibitor Rupintrivir Exerts Cross-Genotypic Anti-Norovirus Activity and Clears Cells from the Norovirus Replicon
  377. Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus
  378. From norbornane-based nucleotide analogs locked in South conformation to novel inhibitors of feline herpes virus
  379. Substituted 2,6-bis(benzimidazol-2-yl)pyridines: A novel chemical class of pestivirus inhibitors that targets a hot spot for inhibition of pestivirus replication in the RNA-dependent RNA polymerase
  380. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
  381. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
  382. Identification of [1,2,3]Triazolo[4,5-d]pyrimidin-7(6H)-ones as Novel Inhibitors of Chikungunya Virus Replication
  383. Are statins a viable option for the treatment of infections with the hepatitis C virus?
  384. In vitro surrogate models to aid in the development of antivirals for the containment of foot-and-mouth disease outbreaks
  385. Antiviral treatment of feline immunodeficiency virus-infected cats with (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine
  386. Binding of Glutathione to Enterovirus Capsids Is Essential for Virion Morphogenesis
  387. New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors
  388. In search of Flavivirus inhibitors part 2: Tritylated, diphenylmethylated and other alkylated nucleoside analogues
  389. Synthesis, biological activity and structure–activity relationship of 4,5-dimethoxybenzene derivatives inhibitor of rhinovirus 14 infection
  392. Trigocherrierin A, a Potent Inhibitor of Chikungunya Virus Replication
  393. Synthesis of Novel Purine-Based Coxsackievirus Inhibitors Bearing Polycylic Substituents at the N-9 Position
  394. Application of a cell-based protease assay for testing inhibitors of picornavirus 3C proteases
  395. Antiviral strategies for hepatitis E virus
  396. Luminescence-based Antiviral Assay for Hepatitis E Virus
  397. Fitness and Virulence of a Coxsackievirus Mutant That Can Circumnavigate the Need for Phosphatidylinositol 4-Kinase Class III Beta
  398. Artemisinin Analogues as Potent Inhibitors of In Vitro Hepatitis C Virus Replication
  399. The Versatile Nature of the 6-Aminoquinolone Scaffold: Identification of Submicromolar Hepatitis C Virus NS5B Inhibitors
  400. Laboratory validation of a lateral flow device for the detection of CyHV-3 antigens in gill swabs
  401. Ribavirin InhibitsIn VitroHepatitis E Virus Replication through Depletion of Cellular GTP Pools and Is Moderately Synergistic with Alpha Interferon
  402. Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative
  403. Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication
  404. The potential of antiviral agents to control classical swine fever: A modelling study
  405. The Viral Polymerase Inhibitor 2'-C-Methylcytidine Inhibits Norwalk Virus Replication and Protects against Norovirus-Induced Diarrhea and Mortality in a Mouse Model
  406. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication
  407. A Novel, Broad-Spectrum Inhibitor of Enterovirus Replication That Targets Host Cell Factor Phosphatidylinositol 4-Kinase IIIβ
  408. In search of flavivirus inhibitors: Evaluation of different tritylated nucleoside analogues
  409. 3-Biphenylimidazo[1,2-a]pyridines or [1,2-b]pyridazines and analogues, novel Flaviviridae inhibitors
  410. Exploration of the in vitro Antiviral Activity of a Series of New Pyrimidine Analogues on the Replication of HIV and HCV
  411. Molecular Biology and Inhibitors of Hepatitis A Virus
  412. Identification of a Series of Compounds with Potent Antiviral Activity for the Treatment of Enterovirus Infections
  413. Phosphatidylinositol 4-Kinase III Beta Is Essential for Replication of Human Rhinovirus and Its Inhibition Causes a Lethal PhenotypeIn Vivo
  414. Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication
  415. 3′,5′Di-O-trityluridine inhibits in vitro flavivirus replication
  416. Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus
  417. Intra-host variation structure of classical swine fever virus NS5B in relation to antiviral therapy
  418. Intervention strategies for emerging viruses: use of antivirals
  419. Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus
  421. Proof of Concept for the Inhibition of Foot-and-Mouth Disease Virus Replication by the Anti-Viral Drug 2′-C-Methylcytidine in Severe Combined Immunodeficient Mice
  422. Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication
  423. Simple and inexpensive three-step rapid amplification of cDNA 5′ ends using 5′ phosphorylated primers
  424. 9-[2-(R)-(Phosphonomethoxy)propyl]-2,6-diaminopurine (R)-PMPDAP and its prodrugs: Optimized preparation, including identification of by-products formed, and antiviral evaluation in vitro
  425. 3C Protease of Enterovirus 68: Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against Picornaviruses
  426. Selective Serotonin Reuptake Inhibitor Fluoxetine Inhibits Replication of Human Enteroviruses B and D by Targeting Viral Protein 2C
  427. Selecting and Characterizing Drug-Resistant Hepatitis C Virus Replicon
  428. Differentiated umbilical cord matrix stem cells as a newin vitromodel to study early events during hepatitis B virus infection
  429. Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
  430. Erratum to “Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus” [J Hepatol 2012;57:246–251]
  431. Safety Assessment in Pigs of an Experimental Molecule with In-Vitro Antiviral Activity Against African Swine Fever
  432. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination
  433. Prostratin and 12-O-Tetradecanoylphorbol 13-Acetate Are Potent and Selective Inhibitors of Chikungunya Virus Replication
  434. Crucial role of the N-glycans on the viral E-envelope glycoprotein in DC-SIGN-mediated dengue virus infection
  435. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication
  436. Inhibition of norovirus replication by the nucleoside analogue 2′-C-methylcytidine
  437. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication
  438. Classical swine fever outbreak containment using antiviral supplementation: A potential alternative to emergency vaccination and stamping-out
  439. A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE
  440. Favipiravir (T-705) inhibits in vitro norovirus replication
  441. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus
  442. 705 Stimulation of Angiogenesis by Hepatitis C Virus (HCV) Non-structural Proteins
  443. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays
  444. The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
  445. Novel 1,2,4-triazole and imidazole derivatives of l-ascorbic and imino-ascorbic acid: Synthesis, anti-HCV and antitumor activity evaluations
  446. An Analogue of the Antibiotic Teicoplanin Prevents Flavivirus Entry In Vitro
  447. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug
  448. Synthesis of novel thienonorbornylpurine derivatives
  451. Efficient synthesis and anti-enteroviral activity of 9-arylpurines
  452. Novel substituted 9-norbornylpurines and their activities against RNA viruses
  453. Evaluation of the antiviral activity of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl)cycloprop-1′-yl]methyl]guanine (A-5021) against equine herpesvirus type 1 in cell monolayers and equine nasal mucosal explants
  454. Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection
  455. Synthesis of novel azanorbornylpurine derivatives
  456. Combating enterovirus replication: State-of-the-art on antiviral research
  457. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors
  458. Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase
  459. Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge
  460. Synthesis, Antiretroviral and Antioxidant Evaluation of a Series of New Benzo[b]furan Derivatives
  461. Antiviral Activity of Bay 41-4109 on Hepatitis B Virus in Humanized Alb-uPA/SCID Mice
  462. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action
  463. Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors
  464. The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication
  465. Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication
  466. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus
  467. Correction to 3′-Deoxy Phosphoramidate Dinucleosides as Improved Inhibitors of Hepatitis C Virus Subgenomic Replicon and NS5B Polymerase Activity
  468. Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
  469. SAR studies of 9-norbornylpurines as Coxsackievirus B3 inhibitors
  470. Broad Antiviral Activity of Carbohydrate-Binding Agents against the Four Serotypes of Dengue Virus in Monocyte-Derived Dendritic Cells
  471. Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication
  472. Towards the design of combination therapy for the treatment of enterovirus infections
  473. European Training Network on (+)RNA Virus Replication and Antiviral Drug Development
  474. 3′,5′di-O-Trityluridine Inhibits Flavivirus (Dengue and Yellow Fever Virus) Replication and Targets the Viral RNA Dependent RNA Polymerase
  475. Classical Swine Fever Outbreak Containment – Antivirals as an Epidemiologically and Economically Viable Alternative to Emergency Vaccination and Culling
  476. Development of New Sulfur-Containing Conjugated Compounds as Anti-HCV Agents
  477. Phosphoramidate Dinucleosides as Inhibitors of Hepatitis C Virus Subgenomic Replicon and NS5B Polymerase Activity
  478. Viral Genome Dynamics During Antiviral Resistance Selection: A First Glimpse into Viral Evolution
  479. A Novel Method—Amenable for High-throughput Screening Purposes—to Quantify Antiviral Activity Against Viruses that Induce Limited CPE
  480. An Analogue of the Antibiotic Teicoplanin Inhibits Dengue Virus Entry In Vitro
  481. An Antiviral Assay to Identify Inhibitors of the Human Metapneumovirus that is Amenable for High-throughput Screening Purposes
  482. Computer-aided Design and Evaluation of Novel Anti-CHIKV Compounds
  483. Coumarins Hybridized with Heterocycles or Ribonucleosides for Eradication of Hepatitis C Virus
  484. In Vitro Combination Therapy with Tegobuvir (GS-9190) is Highly Efficient in Curing Cells from HCV Replicon and in Delaying/Preventing the Development of Antiviral Resistance
  485. Targeting the Flavivirus Helicase
  486. Coumarin−Purine Ribofuranoside Conjugates as New Agents against Hepatitis C Virus
  487. Diagnostic performance and application of two commercial cell viability assays in foot-and-mouth disease research
  488. Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics
  489. Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin Family
  490. Picornavirus non-structural proteins as targets for new anti-virals with broad activity
  493. Adefovir serum levels do not differ between responders and nonresponders
  494. Conformationally locked nucleoside analogues based on the bridgehead substituted 7-oxonorbornane and their antiviral properties
  495. Highly potent and selective inhibition of bovine viral diarrhea virus replication by γ-carboline derivatives
  496. Straightforward synthesis of triazoloacyclonucleotide phosphonates as potential HCV inhibitors
  497. Short and efficient access to imidazo[1,2-a]pyrrolo[3,2-c]pyridine derivatives
  498. DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
  499. Synthesis of Ester Prodrugs of 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as Anti-Poxvirus Agents
  500. Development of a Foot-and-Mouth Disease Infection Model in Severe Combined Immunodeficient Mice for the Preliminary Evaluation of Antiviral Drugs
  501. Hepatitis C Virus Infection of Neuroepithelioma Cell Lines
  502. 3′-Deoxy Phosphoramidate Dinucleosides as Improved Inhibitors of Hepatitis C Virus Subgenomic Replicon and NS5B Polymerase Activity
  503. A Derivate of the Antibiotic Doxorubicin Is a Selective Inhibitor of Dengue and Yellow Fever Virus Replication In Vitro
  504. Tracking the Evolution of Multiple In Vitro Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing
  505. Structure and functionality in flavivirus NS-proteins: Perspectives for drug design
  506. Antiviral strategies to control calicivirus infections
  507. Genomics and structure/function studies of Rhabdoviridae proteins involved in replication and transcription
  508. Design, synthesis, and biological evaluation of novel coxsackievirus B3 inhibitors
  509. S-Aryltriazole acyclonucleosides: Synthesis and biological evaluation against hepatitis C virus
  510. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
  511. Differential Effects of the Putative GBF1 Inhibitors Golgicide A and AG1478 on Enterovirus Replication
  512. Synthesis and antiviral activity of an imidazo[1,2-a]pyrrolo[2,3-c]pyridine series against the bovine viral diarrhea virus
  513. A Novel 9-Arylpurine Acts as a Selective Inhibitor of In Vitro Enterovirus Replication Possibly by Targeting Virus Encapsidation
  514. Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin
  515. In Vitro Selection and Characterization of Hepatitis C Virus Replicons Double or Triple Resistant to Various Non-nucleoside HCV Polymerase Inhibitors
  516. γ-Carboline Derivatives as Potent and Selective Inhibitors of Bovine Viral Diarrhea Virus (BVDV) Replication
  517. Synthesis of Ester Prodrugs of 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as Anti-Poxvirus Agents
  518. Eradication of Persistent Bovine Viral Diarrhea Virus Infection in Cell Culture by Antiviral Treatment: How to Get Ahead of the Viral Evasion Strategy
  519. Inhibition of Hepatitis C Virus Replication by Semisynthetic Derivatives of Glycopeptide Antibiotics
  520. Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care
  521. Replication of not-known-vector flaviviruses in mosquito cells is restricted by intracellular host factors rather than by the viral envelope proteins
  522. Synthesis and antiviral activity of boranophosphonate isosteres of AZT and d4T monophosphates
  523. 9-Arylpurines as a Novel Class of Enterovirus Inhibitors
  524. Synthesis of novel racemic carbocyclic nucleosides derived from 5,6-disubstituted norbornene
  525. Reply:
  526. Norbornane as the novel pseudoglycone moiety in nucleosides
  527. The reduction of CSFV transmission to untreated pigs by the pestivirus inhibitor BPIP: A proof of concept
  528. Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step
  529. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A
  530. The phosphoramidate ProTide approach greatly enhances the activity of β-2′-C-methylguanosine against hepatitis C virus
  531. Cu-Mediated SelectiveN-Arylation of Aminotriazole Acyclonucleosides
  532. Synthesis and Antiviral Evaluation of 2′-C-Methyl Analogues of 5-Alkynyl- and 6-Alkylfurano- and Pyrrolo[2,3-d]Pyrimidine Ribonucleosides
  533. A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase
  534. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach
  535. Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor
  536. Antiviral Activity of Carbohydrate Binding Agents (CBAS) and the Role of DC-SIGN in Dengue Virus and HIV Infection
  537. Comparative Study of the Genetic Barrier and Pathways Towards Resistance of Selective Inhibitors of HCV Replication
  538. In vitro Anti-hepatitis C Virus (HCV) Activities and Resistance Profile of Debio 025, A Non-immunosuppressive Cyclophilin Binding Molecule
  539. Novel 9-Arylpurines, as Selective Inhibitors of In Vitro Enterovirus Replication
  540. Phosphoramidate Protides Greatly Enhance the Anti-HCV Activity of 2′-Methylguanosine
  541. Substituted imidazopyridines as potent inhibitors of HCV replication
  542. Synthesis and SAR of 9-Arylpurines as Novel Inhibitors of Enterovirus Replication
  543. Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection
  544. Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis
  546. Structure−Activity Relationship of New Anti-Hepatitis C Virus Agents: Heterobicycle−Coumarin Conjugates
  547. Proof of concept for the reduction of classical swine fever infection in pigs by a novel viral polymerase inhibitor
  548. Discovery of Novel Arylethynyltriazole Ribonucleosides with Selective and Effective Antiviral and Antiproliferative Activity
  549. Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307
  550. Statins potentiate thein vitroanti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development
  551. ChemInform Abstract: Selective Inhibitors of Picornavirus Replication
  552. Antiviral Agents Acting as DNA or RNA Chain Terminators
  553. Synthesis of novel carbocyclic nucleoside analogues derived from 7-oxabicyclo[2.2.1]heptane-2-methanol
  554. Synthesis of novel racemic carbocyclic nucleoside analogues derived from 4,8-dioxatricyclo[,7]nonane-9-methanol and 4-oxatricyclo[,7]decane-10-methanol, compounds with activity against Coxsackie viruses
  555. Studies of antiviral activity and cytotoxicity ofWrightia tinctoriaandMorinda citrifolia
  556. Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors
  557. Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis
  558. Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues
  559. Selective inhibitors of picornavirus replication
  560. Mouse and Hamster Models for the Study of Therapy against Flavivirus Infections
  561. Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine
  562. Phosphoramidate Dinucleosides as Hepatitis C Virus Polymerase Inhibitors
  563. Assessing the Efficacy of Cidofovir against Herpesvirus-Induced Genital Lesions in Goats Using Different Therapeutic Regimens
  564. A case for developing antiviral drugs against polio
  565. Synthesis and anti-CVB 3 evaluation of substituted 5-nitro-2-phenoxybenzonitriles
  566. Synthesis and antiviral activity of novel derivatives of 2'- -C-methylcytidine
  567. The Crystal Structure of Coxsackievirus B3 RNA-Dependent RNA Polymerase in Complex with Its Protein Primer VPg Confirms the Existence of a Second VPg Binding Site on Picornaviridae Polymerases
  568. Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors
  569. Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication
  570. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond
  571. A Derivate of the Antibiotic Doxorubicin Inhibits Dengue and Yellow Fever Virus Replication In Vitro
  572. Application of the Phosphoramidate Protide Approach to the Antiviral Drug Ribavirin
  573. Discovery of a Novel HCV Helicase Inhibitor by a De Novo Drug Design Approach
  574. Mevastatin Markedly Potentiates the Anti-HCV Activity of Selective Inhibitors of HCV Replication and Delays or Prevents the Emergence of Antiviral Resistance
  575. Synthesis and Antiviral Activity of Various N4-Acyl Derivatives of Cidofovir and its 5-Azacytosine Counterpart, 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine
  576. Treatment of yellow fever
  577. The VIZIER project: Preparedness against pathogenic RNA viruses
  578. Animal models of highly pathogenic RNA viral infections: Encephalitis viruses
  579. Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses
  580. Current and future antiviral therapy of severe seasonal and avian influenza
  581. Does antiviral therapy have a role in the control of Japanese encephalitis?
  582. FDA perspective on antivirals against biothreats: Communicate early and often
  583. Highly pathogenic RNA viral infections: Challenges for antiviral research
  584. International research networks in viral structural proteomics: Again, lessons from SARS
  585. Molecular strategies to inhibit the replication of RNA viruses
  586. NIAID resources for developing new therapies for severe viral infections
  587. New opportunities for field research on the pathogenesis and treatment of Lassa fever
  588. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses
  589. Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock
  590. The Southeast Asian Influenza Clinical Research Network: Development and challenges for a new multilateral research endeavor
  591. Treatment of Argentine hemorrhagic fever
  592. Treatment of Crimean-Congo hemorrhagic fever
  593. Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions
  594. Treatment of hantavirus pulmonary syndrome
  595. Potential Use of Antiviral Agents in Polio Eradication
  596. Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants
  597. The Thiazolobenzimidazole TBZE-029 Inhibits Enterovirus Replication by Targeting a Short Region Immediately Downstream from Motif C in the Nonstructural Protein 2C
  598. Imidazo[4,5-c]pyridines inhibit the in vitro replication of the classical swine fever virus and target the viral polymerase
  599. Synthesis of new benzimidazole–coumarin conjugates as anti-hepatitis C virus agents
  600. Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent
  601. In vitro antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses
  602. Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections
  603. Alkyne-Azide Click Chemistry Mediated Carbanucleosides Synthesis
  604. Cross-Metathesis Mediated Synthesis of New Acyclic Nucleoside Phosphonates
  605. New Analogs of Acyclovir Substituted at the Side Chain
  606. Ester Prodrugs of Cyclic 1-(S)- [3-Hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine:  Synthesis and Antiviral Activity
  607. Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: Further optimization of anti-hepatitis C virus activity
  608. The Imidazopyrrolopyridine Analogue AG110 Is a Novel, Highly Selective Inhibitor of Pestiviruses That Targets the Viral RNA-Dependent RNA Polymerase at a Hot Spot for Inhibition of Viral Replication
  609. Conservation of the pentanucleotide motif at the top of the yellow fever virus 17D 3' stem-loop structure is not required for replication
  610. Potent Inhibition of Genital Herpesvirus Infection in Goats by Cidofovir
  611. Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections
  612. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention
  613. Comparative Activity of Anti-Enteroviral Agents Against Poliovirus Replication In VitroImplications For the End Phase of the Polio Eradication Initiative
  614. Conservation of the pentanucleotide motif at the top of the yellow fever virus 17D 3' stem-loop structure is not required for replication
  615. Enhanced Antiviral Activity of Hexadecyloxypropyl-PME-N6-Cyclopropyl-diaminopurine Against Herpesviruses, Hepatitis B Virus and Vaccinia Virus, In Vitro
  616. In Vivo Antiviral Activity of 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine and its Cyclic Form
  617. Substituted Imidazopyridines as Potent Inhibitors of Hepatitis C Virus Replication that Target the Viral Polymerase
  618. Synthesis and antiviral activities of new acyclic and “double-headed” nucleoside analogues
  619. Synthesis and Antiviral Activity of 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine and its Ester Prodrugs
  620. Synthesis of Novel Types of Anti-Coxsackie Virus Compounds
  621. The Cyclophilin Inhibitor Debio-025 is a Potent Inhibitor of Hepatitis C Virus Replication in vitro With a Unique Resistance Profile
  622. The Imidazopyrrolopyridine Analogue AG110 is a Novel, Highly Selective Inhibitor of Pestivirus Replication and Targets the viral RNA-dependent RNA Polymerase
  623. Thiazolobenzimidazoles, a Novel Class of Enterovirus Inhibitors, Target the 2C Protein
  624. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet
  625. Improved crystallization of the coxsackievirus B3 RNA-dependent RNA polymerase
  626. Cidofovir is effective against caprine herpesvirus 1 infection in goats
  627. In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants
  628. 2′-C-Methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus
  629. Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir
  630. Antiviral Activity of Triazine Analogues of 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) and Related Compounds
  631. Anti-enterovirus activity and structure–activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles
  632. Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A
  633. Substituted 5-Benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A New Class of Pestivirus Inhibitors.
  634. Synthesis of 5-Aryltriazole Ribonucleosides via Suzuki Coupling and Promoted by Microwave Irradiation.
  636. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future
  637. Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: From anti-pestivirus to anti-hepatitis C virus activity
  638. Synthesis, in Vitro Antiviral Evaluation, and Stability Studies of Novel α-Borano-Nucleotide Analogues of 9-[2-(Phosphonomethoxy)ethyl]adenine and (R)-9-[2-(Phosphonomethoxy)propyl]adenine
  639. Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′-C-Methylcytidine, the Active Component of Valopicitabine
  640. Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A new class of pestivirus inhibitors
  641. Synthesis, conformational characteristics and anti-influenza virus A activity of some 2-adamantylsubstituted azacycles
  642. Hepatitis B virus replication causes oxidative stress in HepAD38 liver cells
  643. Selective inhibitors of hepatitis C virus replication
  644. Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin
  645. Introduction to the Special Issue dedicated to Prof. Erik De Clercq for reaching the Professor Emeritus status at the Katholieke Universiteit Leuven
  646. Synthesis of 5-aryltriazole ribonucleosides via Suzuki coupling and promoted by microwave irradiation
  647. Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis
  648. Synthesis of 6-Arylthio Analogs of 2′,3′-Dideoxy-3′-Fluoroguanosine and Their Effect against Hepatitis B Virus Replication
  649. Clinical effect of cidofovir and a diet supplemented with Spirulina platensis in white spot syndrome virus (WSSV) infected specific pathogen-free Litopenaeus vannamei juveniles
  650. Poly(I)-Poly(C12U) but Not Ribavirin Prevents Death in a Hamster Model of Nipah Virus Infection
  651. Heterocyclic rimantadine analogues with antiviral activity
  652. Acute Encephalitis, a Poliomyelitis-like Syndrome and Neurological Sequelae in a Hamster Model for Flavivirus Infections
  653. Synthesis and Anti-BVDV Activity of Acridones As New Potential Antiviral Agents1
  654. The Anti-Yellow Fever Virus Activity of Ribavirin Is Independent of Error-Prone Replication
  655. A Novel, Highly Selective Inhibitor of Pestivirus Replication That Targets the Viral RNA-Dependent RNA Polymerase
  656. Selective inhibitors of the replication of poxviruses
  657. P.091 Selection and phenotypic characterization of multiple drug resistant variants in patients with chronic hepatitis B
  658. Synthesis and Antiviral Evaluation of Cyclic and Acyclic 2-Methyl-3-hydroxy-4-pyridinone Nucleoside Derivatives
  659. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replicationin vitro
  660. Viral load quantitation of SARS-coronavirus RNA using a one-step real-time RT-PCR
  661. Preliminary report of anti-hepatitis C virus activity of chloroquine and hydroxychloroquine in huh-5-2 cell line
  662. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection
  663. Synthesis and primary antiviral activity evaluation of 3-hydrazono-5-nitro-2-indolinone derivatives
  664. Corrigendum to “Selective inhibition of hepatitis B virus replication by RNA interference” [Biochem. Biophys. Res. Commun. 309 (2003) 482–484]
  665. An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge
  667. Growth kinetics of SARS-coronavirus in Vero E6 cells
  668. Novel Acyclic Nucleoside Phosphonate Analogues with Potent Anti-Hepatitis B Virus Activities
  669. The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase
  670. Synthesis and Antiviral Evaluation of Cis-Substituted Cyclohexenyl and Cyclohexanyl Nucleosides
  671. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
  672. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections
  673. Rodent models for the study of therapy against flavivirus infections
  674. Rodent models for the study of therapy against flavivirus infections
  675. Exchanging the Yellow Fever Virus Envelope Proteins with Modoc Virus prM and E Proteins Results in a Chimeric Virus That Is Neuroinvasive in SCID Mice
  676. Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia
  677. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein–Barr virus (EBV) by a quantitative real-time PCR assay
  678. The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis
  679. In vivomonitoring of acute flavivirus (Modoc) encephalitis with regional and whole-brain quantitative diffusion magnetic resonance imaging
  680. Heterocyclic rimantadine analogues with antiviral activity
  681. Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives
  682. Synthesis and Antiviral Evaluation of Ribavirin Congeners Containing a Hexitol Moiety
  683. Selective Inhibitors of Hepatitis B Virus Replication
  684. Selective inhibition of hepatitis B virus replication by RNA interference
  685. The acyclic nucleoside phosphonate analogues, adefovir, tenofovir and PMEDAP, efficiently eliminate banana streak virus from banana (Musa spp.)
  686. Are the 2-Isomers of the Drug Rimantadine Active Anti-Influenza a Agents?
  687. Spiro[pyrrolidine-2,2′-adamantanes]: synthesis, anti-influenza virus activity and conformational properties
  688. A rapid and convenient variant of fusion-PCR to construct chimeric flaviviruses
  689. Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice
  690. Ribavirin Derivatives with a Hexitol Moiety: Synthesis and Antiviral Evaluation
  691. Inhibition of coxsackie B3 virus induced myocarditis in mice by 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile
  692. Impact of Direct Virus-Induced Neuronal Dysfunction and Immunological Damage on the Progression of Flavivirus (Modoc) Encephalitis in a Murine Model
  693. Prospects for Antiviral Therapy
  694. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives
  695. Impact of Direct Virus-Induced Neuronal Dysfunction and Immunological Damage on the Progression of Flavivirus (Modoc) Encephalitis in a Murine Model
  696. Human Herpesvirus 8 Gene Encodes a Functional Thymidylate Synthase
  697. Gammaherpesviruses encode functional dihydrofolate reductase activity
  698. Genome sequence analysis of Tamana bat virus and its relationship with the genus Flavivirus
  699. Effect of 5-Iodo-2′-Deoxyuridine on Vaccinia Virus (Orthopoxvirus) Infections in Mice
  700. 2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections
  701. Complete genome sequence of Montana Myotis leukoencephalitis virus, phylogenetic analysis and comparative study of the 3′ untranslated region of flaviviruses with no known vector
  702. Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis
  703. Antiviral and immunomodulatory activity of the metal chelator ethylenediaminedisuccinic acid against cytomegalovirus in vitro and in vivo
  704. Sulphated and Sulphonated Polymers Inhibit the Initial Interaction of Hepatitis B Virus with Hepatocytes
  705. Complete Genome Sequence, Taxonomic Assignment, and Comparative Analysis of the Untranslated Regions of the Modoc Virus, a Flavivirus with No Known Vector
  706. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties
  707. In vitro Activity of Polyhydroxycarboxylates against Herpesviruses and Hiv
  708. Novel 3-(2-Adamantyl)pyrrolidines with potent activity against influenza A virus—identification of aminoadamantane derivatives bearing two pharmacophoric amine groups
  709. A chemiluminescence detection method of hantaviral antigens in neutralisation assays and inhibitor studies
  711. Angiogenesis: regulators and clinical applications
  712. Anti-herpesvirus activity of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl)-cycloprop-1′-yl]methyl]guanine (A-5021) in vitro and in vivo
  713. The anti-herpesvirus activity of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl)cycloprop-1′-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil
  714. Efficacy of 2-Amino-7-(1,3-Dihydroxy-2-Propoxymethyl)Purine for Treatment of Vaccinia Virus (Orthopoxvirus) Infections in Mice
  715. A Novel Model for the Study of the Therapy of Flavivirus Infections Using the Modoc Virus
  716. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8
  717. Effect of TNP-470 (AGM-1470) on the Growth of Rat Rhabdomyosarcoma Tumors of Different Sizes
  718. Potent inhibition of hemangiosarcoma development in mice by cidofovir
  719. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus
  720. Use of Cotton Rats to Evaluate the Efficacy of Antivirals in Treatment of Measles Virus Infections
  721. Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV-2 in mice: Impact on the search for vaginal microbicides
  722. Antiviral activity of ganciclovir elaidic acid ester against herpesviruses
  723. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
  724. Perspectives for the Treatment of Infections with Flaviviridae
  725. Perspectives for the Treatment of Infections withFlaviviridae
  726. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture
  727. Hydroxyurea Potentiates the Antiherpesvirus Activities of Purine and Pyrimidine Nucleoside and Nucleoside Phosphonate Analogs
  728. Synthesis and Antiviral and Cytostatic Activities of Carbocyclic Nucleosides Incorporating a Modified Cyclobutane Ring
  729. Budding Yeast as a Screening Tool for Discovery of Nucleoside Analogs for Use in HSV-1 TK Suicide-Gene Therapy
  730. Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation
  731. Modulation of Fibroblast Growth Factor-2 Receptor Binding, Signaling, and Mitogenic Activity by Heparin-Mimicking Polysulfonated Compounds
  732. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro
  733. Potent inhibition of human cytomegalovirus (HCMV) replication by alkenyl guanine analogs with a thiazole[4,5-d]pyrimidine ring
  734. Antitumor Potential of Acyclic Nucleoside Phosphonates
  736. Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir
  737. Polyanion Inhibitors of HIV and Other Viruses. 7. Polyanionic Compounds and Polyzwitterionic Compounds Derived from Cyclodextrins as Inhibitors of HIV Transmission
  738. The Antiherpesvirus Activity of H2G [(R)-9-[4-Hydroxy-2-(Hydroxymethyl)Butyl]Guanine] Is Markedly Enhanced by the Novel Immunosuppressive Agent Mycophenolate Mofetil
  739. 7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase
  740. Broad-Spectrum Antiviral Activity and Mechanism of Antiviral Action of the Fluoroquinolone Derivative K-12
  741. Synthesis, Antiviral and Cytostatic Activities of Carbocyclic Nucleosides Incorporating a Modified Cyclopentane Ring. Part 2:1Adenosine and Uridine Analogues
  742. Inhibitory Effects of Novel Nucleoside and Nucleotide Analogues on Epstein—Barr Virus Replication
  743. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells
  744. The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo
  745. Intracellular Metabolism of the N7-Substituted Acyclic Nucleoside Analog 2-Amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, a Potent Inhibitor of Herpesvirus Replication
  746. Differential anti-hepatitis B virus activity in vitro of three potent of inosine monophosphate dehydrogenase inhibitors: mycophenolic acid (MPA), 5-ethynyl-1-β-d-ribofuranosyli-midazole-4-carboxamide (EICAR) and ribavirin
  747. Inhibitory effect of 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) on hepatitis B virus replication in vitro
  748. The influences of immunosuppressive agents on HBV replication in vitro
  749. In Vitro and In Vivo Inhibition of Murine Gamma Herpesvirus 68 Replication by Selected Antiviral Agents
  750. Antiviral drug susceptibility of human herpesvirus 8.
  751. Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses
  752. Antiviral activity of a novel compound P-4018 against different strains of herpes simplex virus in vitro and in vivo
  753. Differential antiviral activity of several IMP dehydrogenase inhibitors
  754. Mycophenolate Mofetil markedly enhances the antiviral activity of acyclovir, ganciclovir and penciclovir against herpes simplex virus (wild type and TK− strains) and human cytomegalovirus
  755. Synthesis and antiviral evaluation of benzyl-substituted thiopurine and tiazofurin derivatives
  756. HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections
  757. Nucleosides and Nucleotides. Part 154. New Neplanocin Analogues. VIII. Synthesis and Biological Activity of 6'-C-Ethyl, -Ethenyl, and -Ethynyl Derivatives of Neplanocin A.
  758. Mechanism of the Antiviral Activity of New Aurintricarboxylic Acid Analogues
  759. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections
  760. Polyanion Inhibitors of Human Immunodeficiency Virus and Other Viruses. Part 2. Polymerized Anionic Surfactants Derived from Amino Acids and Dipeptides†
  761. Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2
  762. Differential antiviral activity of derivatized dextrans
  763. Human cytomegalovirus modulates the Ca2+ response to vasopressin and ATP in fibroblast cultures
  764. Anti-HIV and anti-HCMV Activities of New Aurintricarboxylic Acid Analogues
  765. Human Cytomegalovirus Stimulates Thymidylate Synthase in Human Embryonic Lung Cells: A Possible Target for Anti-HCMV Therapy?
  766. In vivo Antiretroviral Efficacy of Oral bis(POM)-PMEA, the bis(Pivaloyloxymethyl)prodrug of 9-(2-Phosphonylmethoxyethyl) adenine (PMEA)
  767. Absence of Infectious Retinitis after Injection of Human Cytomegalovirus into Rabbit Eyes
  768. In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine
  769. The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication.
  770. Host Defense Mechanisms Against Murine Cytomegalovirus Infection Induced by Poly l:C in Severe Combined Immune Deficient (SCID) Mice
  771. Calcineurin as a possible new target for treatment of Parkinson's disease
  772. Antiviral activity of a sulphated polysaccharide from the red seaweed nothogenia fastigiata
  773. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion.
  774. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication
  775. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice
  776. In vitro Activity of a Novel Series of Polyoxosilicotungstates against Human Myxo-, Herpes- and Retroviruses
  777. Inhibitory activity of S-adenosylhomocysteine hydrolase inhibitors against human cytomegalovirus replication
  778. Protective activity of lipid A analogue GLA-60 against murine cytomegalovirus infection in mice
  779. Protective activity of the lipid A analogue GLA-60 against murine cytomegalovirus infection in immunodeficient mice
  780. Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo
  781. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice
  782. Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice
  783. Strategies for the treatment and prevention of cytomegalovirus infections
  784. Therapy for herpesvirus infections
  785. Poly(Hydroxy)Carboxylates as Selective Inhibitors of Cytomegalovirus and Herpes Simplex Virus Replication
  786. Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate
  787. The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replicati...
  788. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice
  789. Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anticytomegalovirus agents
  790. Inhibitory Effects of Polycations on the Replication of Enveloped Viruses (HIV, HSV, CMV, RSV, Influenza A Virus and Togaviruses) in vitro
  791. Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique
  792. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro
  793. Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro.
  794. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (DHPG)
  795. Sulphated Polymers are Potent and Selective Inhibitors of Various Enveloped Viruses, Including Herpes Simplex Virus, Cytomegalovirus, Vesicular Stomatitis Virus, Respiratory Syncytial Virus, and Toga-, Arena- and Retroviruses
  796. Detection of substances recognized by antisera directed against vertebrate somatotropin, prolactin and placental lactogen, within the brain of the insect Locusta migratoria: A comparison of immunocytochemical localization patterns
  797. Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry
  798. Antiviral Drugs
  799. Antiviral Drugs
  800. Methods in Anti-HCMV Research
  801. Selective inhibitors of the replication of poxviruses
  802. Faculty of 1000 evaluation for Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.
  803. Faculty of 1000 evaluation for Viral reorganization of the secretory pathway generates distinct organelles for RNA replication.
  804. Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases